Teva Announces Availability of a Generic Equivalent of EpiPen Jr® (epinephrine injection, USP) Auto-Injector, 0.15 mg in the United States
JERUSALEM & PARSIPPANY, N.J.–(BUSINESS WIRE[1])–Teva Pharmaceutical Industries (NYSE and TASE: TEVA) today announced availability of the FDA-approved generic version of EpiPen Jr®1 (epinephrine injection, USP) Auto-Injector, 0.15 mg, in the U.S. The product is available in most retail pharmacies, and the Wholesale Acquisition Cost is $3002 for a 2-pack. ”We’re pleased to provide access to Epinephrine Injection (Auto-Injector) in two...